CAS 2086772-26-9

JNJ-64619178

Description:

JNJ-64619178, with the CAS number 2086772-26-9, is a small molecule that has been investigated primarily for its potential therapeutic applications in the treatment of various diseases, particularly in the field of oncology. It functions as a selective inhibitor of specific protein targets involved in cancer cell proliferation and survival. The compound exhibits a unique chemical structure that contributes to its biological activity, characterized by specific functional groups that enhance its binding affinity to target proteins. In preclinical studies, JNJ-64619178 has demonstrated promising efficacy in inhibiting tumor growth and inducing apoptosis in cancer cells. Additionally, its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), are crucial for determining its suitability for clinical use. Ongoing research aims to further elucidate its mechanism of action, optimize its therapeutic profile, and assess its safety and tolerability in human subjects. As with many investigational drugs, the full spectrum of its characteristics and potential applications continues to be explored in clinical trials.

Formula: C₂₂H₂₃BrN₆O₂

Synonyms:

• 1,2-Cyclopentanediol, 3-[2-(2-amino-3-bromo-7-quinolinyl)ethyl]-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-, (1S,2R,3S,5R)-
• JNJ 64619178;JNJ64619178
• JNJ-64619178
• CS-2829

JNJ-64619178

CAS: 2086772-26-9

JNJ-64619178

Purity: ≥98%

Molecular weight: 483.36g/mol

Ref: 54-BUP04212

JNJ-64619178

CAS: 2086772-26-9

JNJ-64619178: selective, oral, pseudo-irreversible PRMT5 inhibitor (IC50: 0.14 nM), effective in lung cancer.

Formula: C₂₂H₂₃BrN₆O₂

Purity: 98.44% - 99.63%

Color and Shape: Solid

Molecular weight: 483.36

Ref: TM-T15624

JNJ-64619178

CAS: 2086772-26-9

JNJ-64619178 is a novel small molecule that targets the methyltransferase domain of the protein PRMT5. The compound has been shown to induce apoptosis in cancer cells, and is currently being evaluated for safety and efficacy in clinical trials. This drug has been shown to have a favorable safety profile and shows no adverse effects on erythropoiesis. JNJ-64619178 is an investigational drug that belongs to the class of compounds that bind to the target site on PRMT5, which is involved in regulating gene expression. It binds to enzymes with methyltransferase activity and inhibits RNA splicing, leading to cell death by apoptosis.

Formula: C₂₂H₂₃BrN₆O₂

Purity: Min. 95%

Molecular weight: 483.36 g/mol

Ref: 3D-LID77226